Rylaze (crisantaspase recombinant)

pCPA File Number: 22356

Negotiation Status:

Concluded with an LOI

Indication(s):

Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.

Sponsor/Manufacturer:

Jazz Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

PC0301-000

pCPA Engagement Letter Issued:

2023-06-02

Negotiation Process Concluded:

2023-07-04